Dr. John Burd

Dr. John Burd is a founder of six companies, including Dexcom, a leader in continuous glucose monitoring with a market cap of $46 billion. He has dedicated his career to developing products that enhance the lives of people with diabetes. Dr. Burd co-founded Sabur Technology and Oculir, Inc., and was a general partner at Windamere Venture Partners, which launched over 15 medical and biotech companies. He also led MiraMedica, sold to Kodak, and founded LXN Corp., acquired by Johnson & Johnson. At Quidel Corp., he directed enzyme immunoassay development and served as executive vice president at Mast Immunosystems. Dr. Burd holds 25 patents, has authored 40 scientific articles, and developed Lysulin™, a supplement aimed at managing diabetes. His personal connection to diabetes, stemming from family experiences, has driven his innovations. He has been inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for clinical chemistry innovation.